Allied Corp. Announces Initiation of Its First Three Major Commercial Exports of Cannabis Flower From Colombia to International Markets
Allied Corp (OTCQB: ALID) has announced the initiation of three significant commercial exports of Colombian-produced dried cannabis flower, totaling 2,500 kilograms. These exports include shipments to Australia and two to the United States, aligning with recent regulatory approvals. This milestone follows a monthly supply agreement for 1,000 kilograms of cannabis flower for a U.S. operator, leveraging Colombia's newfound export regulations. CEO Calum Hughes emphasized the achievement as a result of years of strategic relationship building and production excellence.
- Initiated three major commercial exports totaling 2,500 kilograms.
- Successful export agreement to Australia, marking a first for Allied.
- Utilization of established contracts for U.S. exports, aligning with regulatory approvals.
- None.
KELOWNA, British Columbia, April 21, 2022 (GLOBE NEWSWIRE) -- Allied Corp. ("Allied" or the “Company”) (OTCQB: ALID) is pleased to announce that it has initiated three major commercial exports of Colombian-produced dried cannabis flower. One export is intended for Australia, and the other two exports are intended for the United States. The starting export volumes are for 1000, 1000 and 500 kilograms respectively.
Allied only exports cannabis flower to countries where it is legal to do so (for example, in the United States the THC levels need to be less than
As per the press release made on October 20, 2021, Allied signed a monthly supply agreement with a US-based multi-state operator for a supply of 1000 kilograms of Colombian flower (under
As per the press release made on November 24, 2021 describing the Allied Inside™ supply chain to bring a monthly supply of 2000 kilograms of CBD flower to the US market for the Veterans For Healing CBD cigarettes. Allied has initiated a 500 kilogram export as a part of the 2000 kilogram monthly supply agreement signed in this agreement of November 2021.
In addition to this, as per the press release made on September 20, 2021, Allied submitted its first import permit application to the Australian Department of Health for the import of 1000 kilograms of dried cannabis flower from Colombia. This dried flower import permit application took four months to achieve approval and is the first of its kind for Allied. With this approval, Allied has initiated the export of the first shipment as per the 1000kgs supply agreement destined for Australia.
“1000 kilograms of vacuum sealed packaged cannabis flower is quite the sight to see. We couldn’t be more proud of this monumental achievement. It has taken years of relationship building, international negotiations and precise production knowledge to pull this off. Scaling production to these volumes is not easy with the stringent quality assurance limits for international standards needing to be met. Allied’s disease and pest management program, anti-microbial, heavy metal and anti-mold and yeast program have all led us to this success. As we continue to service the contracts that we have in hand we only expect our monthly volumes to continue to grow,” said Mr. Calum Hughes, CEO and Chairman of Allied Corp.
About Allied Corp. – CLICK HERE
Click here for Allied Inside™ business model website: CLICK HERE
Allied Corp. is an international cannabis company with its main production center in Colombia and is one of the few companies that has exported from Colombia internationally. In preparation for the possible legalization of cannabis by the US Federal Government, Allied also has the option to purchase a US cannabis license in the US (Nevada) exercisable if such were to happen. In addition to this, Allied has three CBD-brands to market with products selling in the United States. Lastly, Allied has both Cannabinoid and psilocybin products in the pharmaceutical development track seeking pharma drug indications for depression, anxiety and PTSD.
Investor Relations:
ir@allied.health
1-877-255-4337
Forward-Looking Statements:
This press release contains “forward-looking information” within the meaning of applicable securities laws in Canada or “forward-looking statements” made pursuant to the “safe harbour” provisions of the United States Private Securities Litigation Reform Act of 1995 (collectively, “forward-looking information”). Forward-looking information may relate to the Company’s future outlook and anticipated events, plans or results, and may include information regarding the Company’s objectives, goals, strategies, future revenue or performance and capital expenditures, and other information that is not historical information. Forward-looking information can often be identified by the use of terminology such as “believe,” “anticipate,” “plan,” “expect,” “pending,” “in process,” “intend,” “estimate,” “project,” “may,” “will,” “should,” “would,” “could,” “can,” the negatives thereof, variations thereon and similar expressions. The forward-looking information contained in this press release is based on the Company’s opinions, estimates and assumptions in light of management’s experience and perception of historical trends, current conditions and expected future developments, as well as other factors that management currently believes are appropriate and reasonable in the circumstances. Forward looking statements in this press release include the following: that Allied is leveraging the conditions in its Colombia grow operation and future Kelowna location to support its Research and Development efforts; that Allied is making important strides forward to position itself as a leader in the medical cannabis space, that Allied intends to make a series of proposed trademark and other intellectual property protection filings, as part of the Company’s Intellectual Property and Pharma Development (IP&PD) Strategy, statements respecting the joint development, manufacturing, and introduction of TACTICAL RELIEF™ branded products, and the use of proceeds from the offering of convertible notes.
There can be no assurance that the underlying opinions, estimates and assumptions will prove to be correct. Risk factors that could cause actual results to differ materially from forward-looking information in this release include: the Company’s exposure to legal and regulatory risk; the effect of the legalization of adult-use cannabis in Canada and Colombia on the medical cannabis industry is unknown and may significantly and negatively affect the Company’s medical cannabis business; that the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis are not as currently expected; that adverse changes or developments affecting the Company’s main or planned facilities may have an adverse effect on the Company; that the medical cannabis industry and market may not continue to exist or develop as anticipated or the Company may not be able to succeed in this market; risks related to completion of the greenhouse construction in Colombia, risks related to market competition; risks related to the proposed adult-use cannabis industry and market in Canada and Colombia including the Company’s ability to enter into or compete in such markets; that the Company has a limited operating history and a history of net losses and that it may not achieve or maintain profitability in the future; risks related to the Company’s current or proposed international operations; risks related to future third party strategic alliances or the expansion of currently existing relationships with third parties; that the Company may not be able to successfully identify and execute future acquisitions or dispositions or successfully manage the impacts of such transactions on its operations; risks inherent to the operation of an agricultural business; that the Company may be unable to attract, develop and retain key personnel; risks resulting from significant interruptions to the Company’s access to certain key inputs such as raw materials, electricity, water and other utilities; that the Company may be unable to transport its cannabis products to patients in a safe and efficient manner; risks related to recalls of the Company’s cannabis products or product liability or regulatory claims or actions involving the Company’s cannabis products; risks related to the Company’s reliance on pharmaceutical distributors; that the Company, or the cannabis industry more generally, may receive unfavourable publicity or become subject to negative consumer or investor perception; that certain events or developments in the cannabis industry more generally may impact the Company’s reputation or its relationships with customers or suppliers; that the Company may not be able to obtain adequate insurance coverage in respect of the risks that it faces, that the premiums for such insurance may not continue to be commercially justifiable or that there may be coverage limitations and other exclusions which may result in such insurance not being sufficient; that the Company may become subject to liability arising from fraudulent or illegal activity by its employees, contractors, consultants and others; that the Company may experience breaches of security at its facilities or losses as a result of the theft of its products; risks related to the Company’s information technology systems; that the Company may be unable to sustain its revenue growth and development; that the Company may be unable to expand its operations quickly enough to meet demand or manage its operations beyond their current scale; that the Company may be unable to secure adequate or reliable sources of necessary funding; risks related to, or associated with, the Company’s exposure to reporting requirements; risks related to conflicts of interest; risks related to fluctuations in foreign currency exchange rates; risks related to the Company’s potential exposure to greater-than-anticipated tax liabilities; risks related to the protection and enforcement of the Company’s intellectual property rights, or the intellectual property that it licenses from others; that the Company may become subject to allegations that it or its licensors are in violation of the intellectual property rights of third parties; that the Company may not realize the full benefit of the clinical trials or studies that it participates in; that the Company may not realize the full benefit of its licenses if the licensed material has less market appeal than expected and the licenses may not be profitable; as well as any other risks that may be further described in and the risk factors discussed in the Company's continuous disclosure including its Management's Discussion and Analysis sections in its Quarterly Reports on Form 10-Q, Annual Reports on Form 10-K and Current Reports on Form 8-K filed under the Company's profile at www.sec.gov.
Although management has attempted to identify important risk factors that could cause actual results to differ materially from those contained in the forward-looking information in this presentation, there may be other risk factors not presently known to the Company or that the Company presently believes are not material that could also cause actual results or future events to differ materially from those expressed in such forward-looking information in this presentation. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. Accordingly, readers and viewers should not place undue reliance on forward-looking information, which speaks only as of the date made. The forward-looking information contained in this release represents the Company’s expectations as of the date of this release or the date indicated, regardless of the time of delivery of the presentation. The Company disclaims any intention, obligation or undertaking to update or revise any forward-looking information, whether as a result of new information, future events or otherwise, except as required under applicable securities laws.
FAQ
What recent developments has Allied Corp (ALID) announced regarding cannabis exports?
How many kilograms of cannabis flower has Allied Corp exported to Australia?
What are the export volumes for Allied Corp's shipments to the United States?
When did Colombia approve the regulations for cannabis flower exports?
